RBDCOV

In healthcare, inclusivity is not just a moral imperative, it is also a strategic necessity for achieving widespread immunity to infections and diseases, like COVID-19, and advancing public health outcomes.

The European Commission has granted a fifteen-month extension to continue with the RBDCOV Project. So far, 240 volunteers have been recruited across all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy,

The European Commission has granted a 15-month extension to the RBDCOV project, allowing researchers additional time to recruit volunteers for the HH-3 clinical trial. This trial assesses the efficacy,

One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus

The RBDCOV project,